CAS 1071066-97-1 | CEBR-002 : Cebra/padol hemicitrate
(World's Largest Pharmaceutical Supplier)

CAS 1071066-97-1 is a chemical compound with the molecular formula C16H21N5O2. It is also known as Alectinib, which is a medication used to treat non-small cell lung cancer (NSCLC) that has a specific genetic mutation.

Alectinib works by inhibiting an enzyme called ALK (anaplastic lymphoma kinase), which is involved in the growth and spread of cancer cells that have the ALK gene mutation. By blocking this enzyme, Alectinib can slow or stop the growth of NSCLC tumors with this mutation.

Alectinib can be taken orally twice daily. It has been shown to be effective in treating ALK-positive NSCLC, both as initial therapy and for patients who have already received other treatments.

However, like all medications, Alectinib can cause side effects such as fatigue, nausea, and constipation. In rare cases, it may also cause more serious side effects such as liver damage or pneumonitis.

It is important to note that Alectinib should only be used under the guidance of a healthcare professional and in accordance with its prescribed dosage. It may not be suitable for all patients, particularly those with certain medical conditions such as liver disease or heart rhythm disorders, and regular monitoring is necessary to ensure its effectiveness and safety.

In summary, CAS 1071066-97-1 is a chemical compound with medical uses as a medication for non-small cell lung cancer with the ALK gene mutation. It is effective in inhibiting the growth of cancer cells with this mutation, but should be used with caution and under the guidance of a healthcare professional due to potential side effects.